AI

HONG KONG, Dec. 04, 2025 (GLOBE NEWSWIRE) — GPTBots.ai, a leading enterprise AI agent platform, is excited to attend the AXIES 2025 Annual Conference in Sapporo, Japan. As the most authoritative and influential annual event in Japan’s higher education informatization sector, the conference attracted approximately 1,700 university IT leaders, CIOs, researchers, and technical experts from across the country.

GPTBots showcased alongside international leaders such as Microsoft Copilot and Salesforce, with a special focus on the diverse and innovative applications of AI Agents in the education industry—including campus intelligent customer service, academic knowledge retrieval, and administrative process automation—which drew significant attention and active engagement from participating universities and technology enterprises.

(Live DEMO Presentation)

Focusing on University Needs: Showcasing Practical AI Agent Applications
At the conference, GPTBots highlighted its platform’s practical applications tailored to the real needs of universities in intelligent services and management, with a focus on the following scenarios:

• Campus Intelligent Customer Service: Automatically responds to FAQs and student service inquiries, enhancing service response efficiency.
• Intelligent Knowledge Base Retrieval: Enables faculty and students to conveniently search for campus regulations, procedures, and academic resources in one place.
• Administrative Process Automation: Facilitates the automated processing of academic affairs, work order approvals, HR inquiries, and other administrative tasks.
• Academic Research Support: Provides teachers and researchers with intelligent tools for information retrieval and data organization.

During the exhibition, the GPTBots booth attracted IT leaders from universities such as Hokkaido University, Shizuoka University, and Chiba Institute of Technology for in-depth discussions. Some university representatives shared their experiences in exploring generative AI and expressed strong interest in the potential of AI Agents to enhance campus service efficiency and management capabilities.

Product Capabilities: Empowering the Digital Transformation of Education
The GPTBots platform is built around no-code, visual development as its core feature, aiming to lower the barrier to AI adoption and help universities quickly deploy and customize intelligent agents. The platform offers the following capabilities:

• Multi-model Integration and Intelligent Scheduling: Supports integration with leading large language models such as OpenAI and Claude.
• Multimodal Knowledge Base: Supports knowledge management and retrieval across multiple data types, including text, images, and videos.
• Visual Workflow Configuration: Allows university administrators to flexibly adjust workflows based on actual business needs.
• Enterprise-grade Security and Compliance: Supports on-premises deployment, data encryption, and permission management to ensure data security.
• Open Integration: Seamlessly connects with academic affairs, OA, LMS, and other systems to support diverse campus scenarios.

Compliance First: Safeguarding University Data Security
GPTBots places great emphasis on data security and compliance. The platform supports on-premises deployment and multi-level permission management, helping universities better protect core data and user privacy throughout their digital transformation journey.

Continuous Exploration: Advancing Deep Integration of AI and Education
Through this AXIES conference, GPTBots gained deeper insights into the practical needs and industry trends of Japanese universities in their digital transformation journey. Looking ahead, GPTBots will continue to strengthen communication and collaboration with universities and industry partners, promote the implementation of AI Agents in educational scenarios, and jointly explore new pathways for building smart campuses.

About GPTBots
GPTBots.ai is an enterprise AI agent platform that enables organizations to build, deploy, and manage intelligent agents for customer service, workflow automation, compliance, and more. With a no-code builder, robust security, and flexible deployment options, GPTBots accelerates AI adoption and delivers measurable results.

Media Contact:
Ida
Marketing Specialist
marketing@gptbots.ai

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9b52ea25-98f5-451a-8974-58e78899b5fb

AI-Driven Risk Prediction for Breast, Prostate and Pancreatic Cancers

TOKYO, Dec. 05, 2025 (GLOBE NEWSWIRE) — A.D.A.M. Innovations Co. (Japanese Name: Genesis Healthcare Co.) (“A.D.A.M. Innovations” or the “Company”), Japan’s leading AI-driven genomics company, today announced the release of three new first-of-their-kind cancer prediction models for its GeneLife GeneAI Forecast platform: breast cancer (women), prostate cancer (men), and pancreatic cancer (unisex), developed using the largest Japanese population genetic database built by the company over 22 years of operation, improving relevance compared with western-derived tools.

With these three additional cancer models, GeneAI Forecast, supported by Japan’s largest commercial genomic population database, now offers a total of 11 unique predictive models for diseases with rising mortality. The release of these models advances GeneLife GeneAI Forecast’s mission to deliver personalized, prevention-focused health insights for the Japanese and broader East Asian population.

Expanding AI-Powered Prevention

GeneAI Forecast uses A.D.A.M. Innovations’ extensive genomic database, built from 2.9 million completed tests, and combines genetic data with lifestyle factors such as BMI, smoking, alcohol consumption, and several other biomarkers.

This dynamic system provides users a personalized baseline risk and illustrates how lifestyle modifications can impact their long-term health. High-risk individuals can use these insights to optimize their lifestyle choices, reduce disease onset risk, or support early detection.

The three new models join existing predictive forecasts for stroke, myocardial infarction, type 2 diabetes, hypertension, chronic kidney disease, lung cancer, stomach cancer, and colorectal cancer.

GeneLife consumers can access the full line of Gene AI Forecast features through the Genesis CONNECT and WGS CONNECT subscription plans.

Designed for Japanese and East Asian Populations

“These new cancer models reflect our commitment to bringing AI-driven, personalized prevention into everyday life,” said Michel Mommejat, President of A.D.A.M. Innovations. “We aim to help individuals understand their risks and support a more proactive approach to early prevention and intervention, leading to long-term health and longevity.”

For additional information, please visit:
www.genelife.jp
www.adam-innovations.com

About A.D.A.M. Innovations Co.

Founded in 2004 in Tokyo, A.D.A.M. Innovations (formerly Genesis Healthcare Co.) is a pioneer in genomics, AI, and precision health solutions. The company develops cutting-edge technologies spanning consumer genetics, clinical diagnostics, and AI-driven R&D data platforms. To date, A.D.A.M. Innovations has conducted more than 2.8 million genetic tests and maintains the largest R&D genomic database of the Japanese population.

About GeneLife
GeneLife is the consumer genomic brand of A.D.A.M. Innovations. GeneLife, brings genetic testing directly to individuals through at-home kits and e-commerce channels. With a 74% market share (source: Fuji Kimera), GeneLife stands as the market leader, delivering personalized health and wellness insights to empower better living and longevity.

GeneLife, GeneAI Forecast are registered trademarks of A.D.A.M. Innovations Co.

Corporate contact:
Email: press@adam-innnovations.com

Media Relations:
Crocker Coulson
Email: Crocker.Coulson@aumadvisors.com
+1 (646) 652-7185

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/05d63b3d-36ed-44da-b976-b579fed900e4

SHANGHAI, Nov. 27, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, and Tencent Healthcare jointly launched a comprehensive “AI+Chronic Disease Management” solution, marking a major step in the wider deployment of artificial intelligence across China’s healthcare sector. The partnership provides industry partners with an integrated technology pipeline, from model training and scenario verification to deployment, aimed at advancing chronic-disease management into a new phase of intelligent, and high-efficiency service delivery.

The solution is built on Fangzhou’s AI+H2H (Hospital to Home) ecosystem, a core architecture that embeds proprietary large-model capabilities into chronic-disease workflows. Tencent Cloud, as a leading cloud services provider, offers extensive capabilities in core technological domains including cloud computing, big data, and artificial intelligence. This strategic collaboration will provide a robust technological foundation for the transformation of AI-enhanced chronic disease management.

Fangzhou Inc. and Tencent Healthcare jointly launched a comprehensive “AI+Chronic Disease Management” solution

Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, remarked: “By combining Fangzhou’s specialized healthcare and chronic disease management expertise with Tencent Healthcare’s industrial-grade infrastructure, we are bringing validated, scalable AI capabilities to the entire healthcare ecosystem, and setting a new standard for the evolution of chronic-disease management in China.”

This launch follows Fangzhou’s recent AI growth momentum. The October introduction of the Company’s “medical report interpretation” feature saw particularly strong adoption, addressing a widespread patient need to better understand complex lab results. Rising engagement levels and session frequency also reflect growing user confidence in AI capabilities.

Safety and compliance remain central to Fangzhou’s approach. To address the risk of AI hallucinations in sensitive clinical settings, the company has implemented multiple layers of protection, including reinforcement learning with curated knowledge bases, rule-based supervision, and medical-scenario alignment checks.

Fangzhou has built its model on Tencent Healthcare’s TI platform, leveraging one-stop training, evaluation and deployment pipelines to enable continuous model optimization. Tencent Healthcare’s vector database, capable of storing hundreds of billions of domain-specific medical knowledge entries, provides millisecond-level semantic retrieval and improves the accuracy and factuality of RAG-based outputs. For compliance assurance, Tencent Healthcare’s AI security WAF supplies fine-grained threat detection and encrypted safeguarding of sensitive medical data, ensuring the solution aligns with regulatory standards for clinical AI.

The partnership aligns closely with the National Health Commission’s recently issued guidelines on developing safe, standardized “AI + healthcare” applications. Both companies indicated their joint solution will help accelerate digital transformation in chronic care, strengthen medical-service delivery, and support long-term national health goals under the “Healthy China 2030” initiative.

About Tencent Healthcare
Tencent Healthcare, as Tencent’s healthcare service platform, leverages the WeChat ecosystem and artificial intelligence technologies to build an integrated service system.

About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/59e0d579-b2b4-4fae-9e75-679ee1218273